Brodalumab for the treatment of plaque psoriasis: up-to-date

Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials

(2018) Mark G. Lebwohl et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CME Part I Psoriasis: Which Therapy for Which Patient Psoriasis comorbidities and preferred systemic agents

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

CME Part II Psoriasis: Which Therapy for Which Patient Focus on special populations and chronic infections

(2018) Shivani B. Kaushik et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly

(2018) Vito Di Lernia et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis

(2018) Jason E. Hawkes et al.   JOURNAL OF IMMUNOLOGY

Long-term efficacy of brodalumab for the treatment of moderate-to-severe psoriasis in two pivotal phase 3 clinical trials

(2018)   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials

(2018) Amy McMichael et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression

(2017) J. Koo et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Spotlight on brodalumab in the treatment of moderate-to-severe plaque psoriasis: design, development, and potential place in therapy

(2017) Michael Roman et al.   Drug Design Development and Therapy

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Keratinocyte-Derived IL-17E Contributes to Inflammation in Psoriasis

(2016) Luisa Senra et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Brodalumab and suicidal ideation in the context of a recent economic crisis in the United States

(2016) Melissa J. Danesh et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Psoriasis and the Risk of Depression in the US Population

(2016) Brandon E. Cohen et al.   JAMA Dermatology

Use of brodalumab for the treatment of psoriasis and psoriatic arthritis

(2015) Dario N Kivelevitch et al.   Immunotherapy

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

(2015) Mark Lebwohl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunology of Psoriasis

(2014) Michelle A. Lowes et al.   Annual Review of Immunology

The role of IL-17 in psoriasis

(2014) Mona Malakouti et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Identification of Functional Roles for Both IL-17RB and IL-17RA in Mediating IL-25-Induced Activities

(2014) E. A. Rickel et al.   JOURNAL OF IMMUNOLOGY

Gene Expression Profiles Normalized in Psoriatic Skin by Treatment with Brodalumab, a Human Anti-IL-17 Receptor Monoclonal Antibody

(2014) C. B. Russell et al.   JOURNAL OF IMMUNOLOGY

Keratinocyte Overexpression of IL-17C Promotes Psoriasiform Skin Inflammation

(2013) A. Johnston et al.   JOURNAL OF IMMUNOLOGY

Validation of the Psoriasis Symptom Inventory (PSI), a patient-reported outcome measure to assess psoriasis symptom severity

(2012) Donald M. Bushnell et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

(2012) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin

(2009) C. Johansen et al.   BRITISH JOURNAL OF DERMATOLOGY